Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ACRS vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: ACRS 1 – 5 CGEN Matrix Metrics: ACRS 1 – 9 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACRS carries a Unified Composite Score of 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACRS vs CGEN
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.38
-6.24% 1D
Market Cap $548.0M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.57β · 75% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $3.86 · SMA50: $4.33
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (ACRS 1 – 5 CGEN)

Columns: Metric · ACRS · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E N/M 5.2x
PEG Ratio N/M 1.29x
EV / Revenue 85.6x 2.5x
2. Growth & Scale CGEN
Revenue Growth (YoY) -55.1% +102.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.4M $76M
Market Cap $548.0M $193.2M
3. Profitability & Quality CGEN
Gross Margin N/A 86.2%
Operating Margin -1412.4% 41.3%
Net Profit Margin 0.0% 47.9%
Return on Equity (ROE) -55.5% 57.2%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) -$75M $32M EBITDA
Cash Flow Margin N/A 41.9% EBITDA Mgn
Net Cash / Leverage $1.11 Book/Sh · -55.5% ROE $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACRS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 60.7% (1st %ile) 89.7% (57th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity N/A 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACRS (1) vs CGEN (9)
Institutional Metric ACRS CGEN Criterion Row Edge
Market Capitalization
Scale
$548.0M $193.2M Larger Scale ACRS
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
-55.1% +102.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
-1412.4% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
-55.5% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
26% ($2–$7) 33% ($1–$3) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.57β · 75% Vol 1.44β · 62% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite CGEN
Trailing 12M Revenue (USD)
Operating Scale
$6.4M $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 85.6x EV/Rev 1.29x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($1.11 Book/Sh · -55.5% ROE) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +5.41 pp
ACRS: -2.87% · CGEN: +2.54%
3M Horizon CGEN +30.31 pp
ACRS: -47.52% · CGEN: -17.21%
6M Horizon ACRS +1.97 pp
ACRS: -24.04% · CGEN: -26.01%
1Y Horizon ACRS +10.96 pp
ACRS: +34.13% · CGEN: +23.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACRS Revenue CGEN Revenue ACRS Op. Margin CGEN Op. Margin Margin Leader
FY2018 $10M $20M -1378.3% -130.5% CGEN
FY2019 $0M N/A -2627.3% N/A ACRS
FY2020 $10M $0M -785.4% -1574.8% ACRS
FY2021 $10M $10M -1327.1% -584.6% CGEN
FY2022 $30M $10M -302.0% -471.7% ACRS
FY2023 $30M $30M -311.6% -38.8% CGEN
FY2024 $20M $30M -758.2% -53.4% CGEN
FY2025 $10M $70M -975.9% 43.1% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACRS BREAKDOWN
130d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $548.0M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ ACRS vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACRS carries a Unified Composite Score of 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: ACRS posts -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACRS cumulative revenue shifted +0.0% while CGEN shifted +250.0%. In operating R&D and SG&A reinvestment, ACRS deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.6x EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACRS (-55.5% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 75% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.